197 related articles for article (PubMed ID: 33659204)
1. A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer.
Hu N; Zhu A; Si Y; Yue J; Wang X; Wang J; Ma F; Xu B; Yuan P
Front Oncol; 2020; 10():565384. PubMed ID: 33659204
[TBL] [Abstract][Full Text] [Related]
2. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.
Tan A; Nong L; Wang H; Jia Y; Zhong W; Qin F; Wang H; Tang J; Liu Y; Lu Y
Cancer Biol Ther; 2023 Dec; 24(1):2265055. PubMed ID: 37831547
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA.
Zhu A; Yuan P; Hu N; Li M; Wang W; Wang X; Yue J; Wang J; Luo Y; Ma F; Zhang P; Li Q; Xu B; Cao S; Lippi G; Naito Y; Osman MA; Marta GN; Franceschini G; Orlandi A
Cancer Biol Med; 2021 May; 18(3):875-87. PubMed ID: 34037346
[TBL] [Abstract][Full Text] [Related]
5. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract][Full Text] [Related]
6. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.
Cao M; Lu H; Yan S; Pang H; Sun L; Li C; Chen X; Liu W; Hu J; Huang J; Xing Y; Zhang N; Chen Y; He T; Zhao D; Sun Y; Zhao L; Liu X; Cai L
BMC Cancer; 2023 May; 23(1):463. PubMed ID: 37208633
[TBL] [Abstract][Full Text] [Related]
7. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of apatinib 250 mg combined with chemotherapy in patients with pretreated advanced breast cancer in a real-world setting.
Zhang R; Chen Y; Liu X; Gui X; Zhu A; Jiang H; Shao B; Liang X; Yan Y; Zhang J; Song G; Li H
Front Oncol; 2023; 13():1076469. PubMed ID: 37397355
[TBL] [Abstract][Full Text] [Related]
9. Apatinib with etoposide capsules as a third- or further-line therapy for extensive-stage small cell lung cancer: an open-label, multicenter, single-arm phase II trial.
He Z; Zhou H; Wang J; Li D; Zhang X; Wang P; Ma T; Zhang Y; Tian C; Chen Y; Zou M; Han Y; Xu C; Ma S; Wang L; Wu X; Chen G; Wang Q
Transl Lung Cancer Res; 2021 Feb; 10(2):889-899. PubMed ID: 33718030
[TBL] [Abstract][Full Text] [Related]
10. Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine-Refractory Differentiated Thyroid Cancer: The REALITY Randomized Clinical Trial.
Lin Y; Qin S; Li Z; Yang H; Fu W; Li S; Chen W; Gao Z; Miao W; Xu H; Zhang Q; Zhao X; Bao J; Li L; Ren Y; Lin C; Jing S; Ma Q; Liang J; Chen G; Zhang H; Zhang Y; Zhou X; Sang Y; Hou Z
JAMA Oncol; 2022 Feb; 8(2):242-250. PubMed ID: 34913959
[TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma.
Zhang B; Qi L; Wang X; Xu J; Liu Y; Mu L; Wang X; Bai L; Huang J
Cancer Commun (Lond); 2020 Dec; 40(12):711-720. PubMed ID: 33314747
[TBL] [Abstract][Full Text] [Related]
12. Apatinib for patients with metastatic biliary tract carcinoma refractory to standard chemotherapy: results from an investigator-initiated, open-label, single-arm, exploratory phase II study.
Wang C; Huang M; Geng Q; Li W; Chang J; Tang W; Guo W
Ther Adv Med Oncol; 2021; 13():17588359211039047. PubMed ID: 34484431
[TBL] [Abstract][Full Text] [Related]
13. Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
Yang G; Xu H; Yang L; Xu F; Zhang S; Yang Y; Wang Y
Lung Cancer; 2020 Sep; 147():229-236. PubMed ID: 32739743
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of second-line therapy with apatinib combined with chemotherapy as second-line therapy in advanced gastric cancer: a single-arm, open-label, prospective, multicenter study.
Zhang Y; Xu J; Wang Q; Ling G; Mao Y; Cai M; Yang Y; Mei J; Han Z; Feng J; Wu Y; Shi L; Wen S; Shen B
Ann Transl Med; 2022 Jun; 10(11):641. PubMed ID: 35813347
[TBL] [Abstract][Full Text] [Related]
15. Apatinib for the treatment of metastatic or locoregionally recurrent nasopharyngeal carcinoma after failure of chemotherapy: A multicenter, single-arm, prospective phase 2 study.
Ruan X; Liang JH; Pan Y; Cai R; Zhang RJ; He Z; Yang X; Niu Z; Jiang W
Cancer; 2021 Sep; 127(17):3163-3171. PubMed ID: 34043812
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial.
Tang LQ; Li XY; Li ZM; Liu ZG; Lin MZ; Zhou H; Yu QW; Zhou J; Zhao C; Chen ZB; Wang XC; Peng JY; Chen QY; Fang WF; Yang YP; Zhang B; Xia LP; Hu PL; Hu WH; Li YJ; Mai HQ; Cai XY
BMC Med; 2023 Mar; 21(1):94. PubMed ID: 36927541
[TBL] [Abstract][Full Text] [Related]
18. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
[TBL] [Abstract][Full Text] [Related]
19. Apatinib combined with paclitaxel-based chemotherapy in patients with taxane-resistant advanced gastric cancer: a single-arm exploratory study.
Zhao S; Fan N; Li H; Liu J; Huang F; Chen Y; Zhou M; Yu J; Lin R
Ann Transl Med; 2020 Oct; 8(19):1233. PubMed ID: 33178765
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study.
Ren D; Wang G; Zhang Y; Kan J; Dong Q; Zhao J; Ji F; Li H; Luo Y; Lin M; Li G; Liu Z; Ma X; Guo Q; Zhao F; Shen G; Zhao J
Onco Targets Ther; 2021; 14():4499-4508. PubMed ID: 34434051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]